Choroid Plexus Carcinoma

EVANS, Ga. & AUSTIN, Texas--( BUSINESS WIRE )--The Center for Primary Care (CPC), an independent practice dedicated to providing comprehensive preventative and specialized care, announced today it has formed a new partnership with agilon health inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, accelerating access to value-based primary care in the area. Starting in 2024 through the partnership, CPC will deliver this new model of primary care to further enhance preventative and chronic care for their senior patients. “A value-based approach is the future of health care and agilon understands the importance of exceptional, comprehensive, and affordable value-based primary care,” said Robert M. Clark, D.O., Center for Primary Care. “This partnership will empower our primary care physicians, through a proven model of care, to remain independent and better serve our senior patients while supporting CPC’s mission to provide patients with high-quality care across communities we serve.” CPC, an independent primary care practice, operates across 8 locations in the Central Savannah River Area, which includes communities in Eastern Georgia and Western South Carolina. With 37 primary care physicians (PCPs), CPC is committed to preventative health care as well as the diagnosis and treatment of acute illnesses and chronic conditions. Serving over 76,000 patients of all ages, CPC also offers in-house laboratories and diagnostic imaging services which are exclusively available to their patients. “The newly formed partnership with the Center for Primary Care brings agilon’s Total Care Model to even more communities including senior patients in Eastern Georgia for the first time,” said Steve Sell, chief executive officer, agilon health. “Our team is excited to partner with the Center for Primary Care as they make the move to a full-risk value-based model for their Medicare Advantage patients and primary care physicians.” agilon is accelerating at scale the transition to a value-based, Total Care Model for senior patients that improves outcomes and lowers costs. CPC will join agilon’s 2024 class of new partner organizations, which includes five other physician practices and health systems across the U.S. As of 2024, agilon will be in long-term partnerships with 31 physician groups and health systems across 14 states. About Center for Primary Care (CPC) Center For Primary Care (CPC) is a family and internal medicine practice with 37 primary care physicians and 8 offices in the Central Savannah River Area. CPC's physicians provide comprehensive care for patients of all ages, and diagnostic imaging services. CPC provides weekday evening hours and weekend hours in select locations for established CPC patients with urgent healthcare needs. For more information, visit centerforprimarycare.com . About agilon health agilon health is the trusted partner empowering physicians to transform health care in our communities. Through our partnerships and purpose-built platform, agilon is accelerating at scale how physician groups transition to a value-based Total Care Model for senior patients. agilon provides the technology, people, capital, process, and access to a peer network of 2,700+ PCPs that allow physician groups to maintain their independence and focus on the total health of their most vulnerable patients. Together, agilon and its physician partners are creating the healthcare system we need – one built on the value of care, not the volume of fees. The result: healthier communities and empowered doctors. agilon is the trusted partner in 30+ diverse communities and is here to help more of our nation's leading physician groups and health systems have a sustained, thriving future. For more information about agilon health, visit www.agilonhealth.com and connect with us on Twitter , Instagram , LinkedIn and YouTube .

ROCKVILLE, Md., Feb. 22, 2023 /PRNewswire/ -- An expert consensus statement published today by the Heart Failure Society of America (HFSA) offers best practices in the management of patients on durable Mechanical Circulatory Support (MCS), focusing on pharmacological therapies administered to patients on continuous flow Left Ventricular Assist Devices (LVADs). "Over the last two decades, durable MCS for the management of advanced heart failure has enjoyed a remarkable evolution, generating smaller and more hemocompatible devices with more favorable side-effect profiles, yielding progressive gains in short- and long-term survival. However, proficient medical management of patients on durable LVAD support is necessary to increase their quantity and quality of life," said Barry Trachtenberg, MD lead author and Cardiologist at Houston Methodist Heart and Vascular Center. "This consensus statement will provide clinicians with practical information they need to make decisions and support optimal patient care for the management of this unique population." As patients live longer on LVAD support, attention to the medical management of patients on durable LVAD support is paramount for advancing long-term outcomes. The consensus statement was created to provide a guide in the following areas: Guideline Directed Medical Therapies in Patients on Durable MCS Medical Therapy Directed at Complications Encountered in Patients on Durable MCS Management of Right Ventricular Failure and Pulmonary Hypertension Identifying and Managing Vasoplegia Perioperatively Management of Strokes Management of Arrhythmias Prevention and Treatment of Mucocutaneous Bleeding Management of Infectious Complications Anticoagulation and Antiplatelet Therapy Management Addressing Depression, Anxiety, and Compliance Consideration of Herbal and Nutritional Therapies The authors highlight the following key points: Postoperative long-term GDMT is recommended for ongoing neurohormonal blockade, prevention of heart failure decompensation, arrhythmia suppression, hypertension control and mitigation of renal vascular disease. Most patients with preoperative pulmonary hypertension will experience improvements in pulmonary pressures following LVAD implant, but a minority will experience cPC-PH that can lead to RV dysfunction. Aggressive preoperative optimization to reduce RV wall stress through decongestion and pulmonary vasodilator therapy, followed by careful postoperative monitoring of RV function and afterload, are critical to reduce the risk of early severe RVF. Ongoing close surveillance of LVAD outpatients, monitoring for congestion or complications that can trigger RV dysfunction (excessive LVAD speeds with septal shift, arrhythmias) are crucial for preventing heart failure exacerbation during long term LVAD therapy. Meticulous driveline care for prevention of driveline and LVAD-associated infections is crucial and prompt use of appropriate antibiotics is crucial in patients with infections Current evidence is reviewed for mitigation and treatment of GIB through pharmacologic therapy. While the HeartMate 3 pump confers a lower risk of device thrombosis and ischemic stroke, anticoagulation therapy with warfarin is still required. Patient education about nutritional and herbal therapies is important to reduce the potential for interference with anticoagulant and antiplatelet management. Regular review of programmatic clinical practice guidelines and practitioner adherence to GDMT recommendations, mean arterial pressure goals, and time in therapeutic range for anticoagulation on LVAD support should be considered to ensure optimal outcomes are achieved for more patients on LVAD support. The HFSA Expert Consensus Statement on the Medical Management of Patients on Durable Mechanical Circulatory Support is published in the Journal of Cardiac Failure and available online at . DOI: 10.1016/j.cardfail.2023.01.009 About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org. About the Journal of Cardiac Failure The Journal of Cardiac Failure publishes peer-reviewed manuscripts of interest to clinicians and researchers in the field of heart failure and related disciplines. These include original communications of scientific importance and review articles involving clinical research, health services and outcomes research, animal studies, and bench research with potential clinical applications to heart failure. The Journal also publishes manuscripts that report the design of ongoing clinical trials and editorial perspectives that comment on new developments pertinent to the field of heart failure or manuscripts published in other journals. Learn more at . Media Contact: Laura Poko 301-798-4493, ext. 226 [email protected] SOURCE Heart Failure Society of America